Breast cancer is the most common tumor type among women in the United States, accounting for nearly 30% of cancer diagnoses. While earlier detection and novel therapies have improved survival in recent years, treatment-related toxicities continue to impact quality of life (ACS, 2022). Because toxicities often vary by class of drug prescribed, comprehensive knowledge of each novel therapy class—antibody-drug conjugates, CDK4/6 inhibitors, HER2 tyrosine kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, PARP inhibitors, and PI3 kinase inhibitors—are critical to providing optimal patient-centered care.

In this live symposium, our estemeed nurse faculty will provide expert guidance on the management and supportive care of patients receiving these novel therapies for breast cancer. For an indepth look at each session please CLICK HERE.

We are so pleased to announce the exceptional speakers who will be presenting at ODACon 2022. Throughout the conference attendees will have the opportunity to hear from our panel of distinguished faculty experts during 7 case-based interactive sessions. CLICK HERE to learn more about our esteemed faculty.

This activity is supported by independent grants from Gilead Sciences, Inc. and Puma Biotechnology, Inc.